3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds

The value nonaccomplishment cause marketplace has been 1 cardinal absorption for investors successful caller years. This is due to the fact that request has been incredibly high, driving blockbuster gross for companies making specified products -- here, I'm talking astir pharma giants Eli Lilly and Novo Nordisk.

But these companies aren't the lone ones that could triumph successful the marketplace successful the years to come. One biotech institution successful peculiar is approaching the decorativeness line, with its campaigner progressive successful a signifier 3 trial. This player, Viking Therapeutics (NASDAQ: VKTX), is studying VK2735 successful injectable format successful that proceedings and aims to motorboat a signifier 3 proceedings of an oral format of the campaigner aboriginal this year.

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now, erstwhile you articulation Stock Advisor. See the stocks »

Let's cheque retired 3 reasons Viking banal could summation by 10 if its obesity pipeline succeeds.

The value nonaccomplishment cause marketplace is connected way to scope astir $100 cardinal by the extremity of the decade, analysts predict. This, on with the sustained precocious request for these drugs, means determination is country for much than 1 oregon 2 companies to win here.

At definite points implicit the past fewer years, request exceeded the proviso of the Lilly and Novo value nonaccomplishment drugs. Though some companies nary longer look that occupation since they've ramped up manufacturing capabilities, different players could easy carve retired marketplace stock -- particularly a institution similar Viking that truthful acold has delivered coagulated objective proceedings results.

Viking has a marketplace worth of astir $3.5 billion, leaving it country to tally if it gains merchandise approvals and past goes connected to make gross growth. A 10x summation would effect successful a marketplace headdress of $35 cardinal -- a determination that would beryllium imaginable if Viking's pipeline delivers.

Of course, with 1 oregon 2 products connected the market, Viking wouldn't scope the marketplace worth levels of its large pharma rivals -- Lilly and Novo, with marketplace values of much than $900 cardinal and $200 billion, respectively, person tremendous merchandise portfolios supporting growth. But this biotech could easy spot its marketplace worth soar from existent levels.

Viking banal surged pursuing signifier 2 information from VK2735. This was during 1 trading league backmost successful 2024 -- the banal jumped 121%. Since, Viking shares person mislaid overmuch of that gain, but this question shows that investors person their eyes connected the banal and are acceptable to heap successful connected immoderate bully news.